LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $94.57.

Several equities analysts have weighed in on the company. JMP Securities lifted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st.

LeMaitre Vascular Price Performance

LMAT stock opened at $105.47 on Thursday. LeMaitre Vascular has a one year low of $52.55 and a one year high of $109.58. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 57.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. The company has a fifty day moving average price of $95.80 and a two-hundred day moving average price of $88.23.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period last year, the firm posted $0.33 EPS. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. Research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Glenmede Trust Co. NA increased its position in LeMaitre Vascular by 1.3% in the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after buying an additional 136 shares during the last quarter. Summit Global Investments increased its holdings in LeMaitre Vascular by 2.4% in the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after acquiring an additional 146 shares during the last quarter. Shaker Investments LLC OH raised its stake in LeMaitre Vascular by 1.3% in the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after acquiring an additional 175 shares during the period. NBC Securities Inc. lifted its holdings in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the period. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.